Trial STEP 2 (Davies et al., Lancet 2021) Design Phase 3 / 68 weeks Population 1,210 adults with T2D and overweight or obesity Key result -9.6% body weight (2.4 mg) vs -3.4% placebo
Avoid aluminum-only formulations if you have kidney disease, as aluminum accumulation becomes a concern with prolonged use
NOTE: About deleted recordings
, 2 , 696-701, Schmidberger, J
4.2 Structural modifications shape flavonoid bioactivity 4.2.1 Hydroxylation Among the major structural modifications, hydroxylation is one of the primary determinants of flavonoid bioactivity because it influences redox potential, hydrogen-bonding capacity, metal-chelation, and interactions with biological targets
If you suffer from conditions like IBS (Irritable Bowel Syndrome) or other gastrointestinal issues, BPC-157 may offer additional benefits beyond tissue healing